GlassScriptPhysician profile
Mary Grayson Ford
NPI 1740808906
$5,038.38
in general payments reported to CMS, 2019-2025
20 companies · $1,634 in 2025
The $1,634 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $302 · 2022: $838 · 2023: $1,145 · 2024: $1,119 · 2025: $1,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,733 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,732.57 |
| Education | $165.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,461.45 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $958.63 | 2021-2025 | Airsupra, Fasenra, Tezspire |
| Amgen INC. | $307.35 | 2021-2025 | Tezspire |
| Pharming Healthcare, INC. | $299.37 | 2022-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $297.65 | 2023-2025 | |
| Csl Behring | $282.23 | 2025 | Andembry, Hizentra |
| Regeneron Healthcare Solutions, INC. | $252.26 | 2023-2025 | Dupixent |
| Optinose US, INC. | $216.19 | 2022-2025 | |
| Incyte Corporation | $143.76 | 2022 | |
| Pfizer INC. | $142.51 | 2022-2025 | |
| Glaxosmithkline, LLC. | $108.18 | 2023-2025 | Nucala |
| Biocryst US Sales Co., LLC | $88.41 | 2022-2024 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $86.45 | 2023-2025 | Cuvitru |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Cycle Pharmaceuticals INC | $73.44 | 2025 | Sajazir |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $65.31 | 2024-2025 | Xembify |
| Hikma Pharmaceuticals USA | $57.14 | 2022-2023 | Ryaltris |
| Lilly USA, LLC | $51.03 | 2024-2025 | Ebglyss |
| Ionis Pharmaceuticals, INC. | $37.42 | 2025 | Dawnzera |
| Genentech USA, INC. | $29.61 | 2023 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.